Fast Market Research recommends "Hemispherx Biopharma, Inc. - Product Pipeline Review - 2012" from Global Markets Direct, now available
Boston, MA -- (SBWIRE) -- 11/15/2012 -- Global Markets Direct's pharmaceuticals report, "Hemispherx Biopharma, Inc. - Product Pipeline Review - 2012" provides data on the Hemispherx Biopharma, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Hemispherx Biopharma, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Hemispherx Biopharma, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.
- Hemispherx Biopharma, Inc. - Brief Hemispherx Biopharma, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hemispherx Biopharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Hemispherx Biopharma, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Hemispherx Biopharma, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
View Full Report Details and Table of Contents
Reasons to Get this Report
- Evaluate Hemispherx Biopharma, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Hemispherx Biopharma, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Hemispherx Biopharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Hemispherx Biopharma, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Hemispherx Biopharma, Inc. and identify potential opportunities in those areas.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Hemispherx Biopharma, Inc. - Product Pipeline Review - H2 2011
- Hemispherx Biopharma, Inc. - Product Pipeline Review - Q1 2011
- HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2012
- Lytix Biopharma AS - Product Pipeline Review - 2012
- Synageva BioPharma Corp. - Product Pipeline Review - 2012
- Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT Analysis Review
- ARCA biopharma, Inc. - Product Pipeline Review - 2012
- Can-Fite BioPharma Ltd. - Product Pipeline Review - 2012
- Soligenix, Inc. - Product Pipeline Review - 2012
- Human Papillomavirus Infections - Pipeline Review, H1 2012